Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Web Exclusives
Cholangiocarcinoma
Using Tumor Organoid-Based Functional Analysis to Predict Drug Sensitivities in Patients with Cholangiocarcinoma
Read More
Cholangiocarcinoma
Improving Chemotherapy Combinations and Novel Treatments Are Needed in Advanced Biliary Tract Cancer
Read More
Ovarian Cancer
Quality of Life Maintained with Niraparib in Newly Diagnosed Ovarian Cancer
Read More
Ovarian Cancer
Several Resources Offer Helpful Information on COVID-19 for Cancer Patients
Read More
Ovarian Cancer
PARP Inhibitors Consistently Improve PFS as First-Line Maintenance in Advanced Ovarian Cancer
Read More
Ovarian Cancer
Immunotherapy Triplet Has Significant Clinical Activity in Recurrent Ovarian Cancer
Read More
Ovarian Cancer
Online PARP Inhibitor Education Has Positive Impact on Oncologists’ and OB/GYNs’ Knowledge and Confidence
Read More
Ovarian Cancer
Prepare for Side Effects with Use of PARP Inhibitors as Upfront Maintenance
Read More
Ovarian Cancer
Upfront Maintenance Combination for Advanced Ovarian Cancer Not Ready for Clinical Use
Read More
Ovarian Cancer
No Difference in Overall Survival Between Nivolumab and Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer
Read More
3
4
5
6
7
8
9
Page 6 of 42
Results 51 - 60 of 417